This is an open label study to assess the improvement in the Disease Activity Score for
28-joint counts (DAS28) with ticagrelor given at 90 mg twice daily in patients with RA who
have active disease despite MTX therapy (as defined by the inclusion/exclusion criteria).
There will also be a cross sectional analysis of baseline platelet activity in subjects with
rheumatoid arthritis and osteoarthritis. Subjects in the OA cohort will not receive any study
medication, and will only have one study visit.
Patients will receive 90 mg ticagrelor orally bid. The patients will receive drug for
30-days. Methotrexate dose will remain stable throughout the study duration.